OTC Markets EXMKT - Delayed Quote USD
ContraFect Corporation (CFRXQ)
At close: October 18 at 4:00 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -16.14 | -0.69 | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 1 | -- | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 12/31/2022 | 3/31/2023 | 6/30/2023 | 9/30/2023 |
|---|---|---|---|---|
| EPS Est. | -27.2 | -10.83 | -1.81 | -0.66 |
| EPS Actual | -16.14 | -0.69 | -1.94 | -0.5 |
| Difference | 11.06 | 10.14 | -0.13 | 0.16 |
| Surprise % | 40.70% | 93.60% | -7.20% | 24.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | -0.69 | 0 | -3.44 | -1.5 |
| 30 Days Ago | -0.69 | 0 | -3.44 | -1.5 |
| 60 Days Ago | -0.69 | 0 | -3.44 | -1.5 |
| 90 Days Ago | -0.69 | 0 | -3.44 | -1.5 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CFRXQ | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 3.60% |
| Next Qtr. | -- | -- | -- | 7.90% |
| Current Year | -- | -- | -- | 2.50% |
| Next Year | -- | -- | -- | 13.10% |
| Next 5 Years (per annum) | 12.70% | -- | -- | 11.87% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Upgrade | Maxim Group: Hold to Buy | 4/13/2023 |
Related Tickers
BV3A.SG Bavarian Nordic A/S
9.45
-1.05%
INFIQ Infinity Pharmaceuticals, Inc.
0.0001
0.00%
RGRX RegeneRx Biopharmaceuticals, Inc.
0.0014
0.00%
KANT Kineta, Inc.
0.7100
+1.43%
LSTA Lisata Therapeutics, Inc.
2.9800
-0.33%
BXRXQ Baudax Bio, Inc.
0.0002
+100.00%
ARDS Aridis Pharmaceuticals, Inc.
0.0001
-99.00%
HSTO Histogen Inc.
0.3000
+41.18%
QBIO Q BioMed Inc.
0.0005
+25.00%
BVNKF Bavarian Nordic A/S
30.99
0.00%